Dynavax to Report First Quarter 2025 Financial Results and Host Conference Call on May 6, 2025
Dynavax Technologies (NASDAQ: DVAX), a commercial-stage biopharmaceutical company focused on innovative vaccine development, has scheduled its first quarter 2025 financial results announcement for May 6, 2025, after U.S. market close. The company will host a conference call and audio webcast at 4:30 p.m. ET/1:30 p.m. PT on the same day.
Dynavax currently markets two commercial products: HEPLISAV-B vaccine, approved in the U.S., EU, and UK for hepatitis B virus prevention in adults 18 and older, and CpG 1018 adjuvant, which is used in HEPLISAV-B and various COVID-19 vaccines.
Dynavax Technologies (NASDAQ: DVAX), un'azienda biofarmaceutica in fase commerciale specializzata nello sviluppo di vaccini innovativi, ha programmato l'annuncio dei risultati finanziari del primo trimestre 2025 per il 6 maggio 2025, dopo la chiusura del mercato statunitense. La società terrà una conference call e una webcast audio alle 16:30 ET/13:30 PT dello stesso giorno.
Dynavax commercializza attualmente due prodotti: il vaccino HEPLISAV-B, approvato negli Stati Uniti, nell'UE e nel Regno Unito per la prevenzione dell'epatite B negli adulti dai 18 anni in su, e l'adiuvante CpG 1018, utilizzato in HEPLISAV-B e in diversi vaccini contro il COVID-19.
Dynavax Technologies (NASDAQ: DVAX), una compañía biofarmacéutica en etapa comercial enfocada en el desarrollo innovador de vacunas, ha programado el anuncio de sus resultados financieros del primer trimestre de 2025 para el 6 de mayo de 2025, después del cierre del mercado estadounidense. La empresa realizará una llamada de conferencia y una transmisión en audio a las 4:30 p.m. ET/1:30 p.m. PT del mismo día.
Dynavax comercializa actualmente dos productos: la vacuna HEPLISAV-B, aprobada en EE. UU., la UE y el Reino Unido para la prevención del virus de la hepatitis B en adultos mayores de 18 años, y el adyuvante CpG 1018, que se utiliza en HEPLISAV-B y en varias vacunas contra el COVID-19.
Dynavax Technologies(나스닥: DVAX)는 혁신적인 백신 개발에 주력하는 상업 단계의 바이오제약 회사로, 2025년 1분기 재무 실적 발표를 2025년 5월 6일 미국 시장 마감 후에 예정하고 있습니다. 회사는 같은 날 오후 4시 30분(동부시간)/오후 1시 30분(태평양시간)에 컨퍼런스 콜과 오디오 웹캐스트를 진행할 예정입니다.
Dynavax는 현재 두 가지 상업 제품을 판매 중입니다: 18세 이상 성인의 B형 간염 예방을 위해 미국, EU, 영국에서 승인된 HEPLISAV-B 백신과, HEPLISAV-B 및 여러 COVID-19 백신에 사용되는 CpG 1018 보조제입니다.
Dynavax Technologies (NASDAQ : DVAX), une entreprise biopharmaceutique en phase commerciale spécialisée dans le développement de vaccins innovants, a programmé l'annonce de ses résultats financiers du premier trimestre 2025 pour le 6 mai 2025, après la clôture des marchés américains. La société organisera une conférence téléphonique et une webdiffusion audio à 16h30 ET/13h30 PT le même jour.
Dynavax commercialise actuellement deux produits : le vaccin HEPLISAV-B, approuvé aux États-Unis, dans l'UE et au Royaume-Uni pour la prévention du virus de l'hépatite B chez les adultes de 18 ans et plus, ainsi que l'adjuvant CpG 1018, utilisé dans HEPLISAV-B et plusieurs vaccins contre la COVID-19.
Dynavax Technologies (NASDAQ: DVAX), ein biopharmazeutisches Unternehmen in der kommerziellen Phase, das sich auf die Entwicklung innovativer Impfstoffe spezialisiert hat, hat die Bekanntgabe der Finanzergebnisse für das erste Quartal 2025 für den 6. Mai 2025 nach Börsenschluss in den USA geplant. Das Unternehmen wird am selben Tag um 16:30 Uhr ET/13:30 Uhr PT eine Telefonkonferenz und eine Audio-Webcast veranstalten.
Dynavax vermarktet derzeit zwei kommerzielle Produkte: den HEPLISAV-B-Impfstoff, der in den USA, der EU und Großbritannien zur Prävention des Hepatitis-B-Virus bei Erwachsenen ab 18 Jahren zugelassen ist, sowie den CpG 1018-Adjuvans, der in HEPLISAV-B und verschiedenen COVID-19-Impfstoffen verwendet wird.
- None.
- None.
Dynavax will host a conference call and live audio webcast on Tuesday, May 6, 2025, at 4:30 p.m. ET/1:30 p.m. PT.
The live audio webcast may be accessed through the "Events & Presentations" page on the "Investors" section of the Company's website at https://investors.dynavax.com/events-presentations. A replay of the webcast will be available for 30 days following the live event.
To dial into the call, participants will need to register for the call using the caller registration link. It is recommended that participants dial into the conference call or log into the webcast approximately 10 minutes prior to the call.
About Dynavax
Dynavax is a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines to help protect the world against infectious diseases. The Company has two commercial products, HEPLISAV-B® vaccine [Hepatitis B Vaccine (Recombinant), Adjuvanted], which is approved in the
For Investors/Media:
Paul Cox
pcox@dynavax.com
510-665-0499
Nicole Arndt
narndt@dynavax.com
510-665-7264
View original content to download multimedia:https://www.prnewswire.com/news-releases/dynavax-to-report-first-quarter-2025-financial-results-and-host-conference-call-on-may-6-2025-302434859.html
SOURCE Dynavax Technologies
FAQ
When will Dynavax (DVAX) release Q1 2025 earnings?
What are Dynavax's (DVAX) main commercial products in 2025?
Where is HEPLISAV-B vaccine approved for use?
How can investors access Dynavax's Q1 2025 earnings call?
